Evidence map›Paper›PMID 32401067›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2020

Synthesis of calix[4]azacrown substituted sulphonamides with antioxidant, acetylcholinesterase, butyrylcholinesterase, tyrosinase and carbonic anhydrase inhibitory action.

Mehmet Oguz, Erbay Kalay, Suleyman Akocak, Alessio Nocentini, Nebih Lolak, Mehmet Boga, Mustafa Yilmaz, Claudiu T Supuran

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Mehmet OguzDepartment of Chemistry, University of Selcuk, Konya, Turkey.ORCID http://orcid.org/0000-0002-3999-620X
Erbay KalayKars Vocational School, Kafkas University, Kars, Turkey.
Suleyman AkocakDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Adiyaman University, Adiyaman, Turkey.
Alessio NocentiniNEUROFARBA Department, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze, Florence, Italy.ORCID http://orcid.org/0000-0003-3342-702X
Nebih LolakDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Adiyaman University, Adiyaman, Turkey.
Mehmet BogaDepartment of Analytical Chemistry, Faculty of Pharmacy, Dicle University, Diyarbakir, Turkey.
Mustafa YilmazDepartment of Chemistry, University of Selcuk, Konya, Turkey.
Claudiu T SupuranNEUROFARBA Department, Sezione di Scienze Farmaceutiche, Università degli Studi di Firenze, Florence, Italy.ORCID http://orcid.org/0000-0003-4262-0323
Adıyaman University · TRIstituto Nazionale di Fisica Nucleare, Sezione di Firenze · ITSelçuk University · TRDicle University · TRKafkas University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel calix[4]azacrown substituted sulphonamide Schiff bases was synthesised by the reaction of calix[4]azacrown aldehydes with different substituted primary and secondary sulphonamides. The obtained novel compounds were investigated as inhibitors of six human (h) isoforms of carbonic anhydrases (CA, EC 4.2.1.1). Their antioxidant profile was assayed by various bioanalytical methods. The calix[4]azacrown substituted sulphonamide Schiff bases were also investigated as inhibitors of acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and tyrosinase enzymes, associated with several diseases such as Alzheimer, Parkinson, and pigmentation disorders. The new sulphonamides showed low to moderate inhibition against hCAs, AChE, BChE, and tyrosinase enzymes. However, some of them possessed relevant antioxidant activity, comparable with standard antioxidants used in the study.

Indexed as

AcetylcholinesteraseAntioxidantsButyrylcholinesteraseCalixarenesCarbonic Anhydrase InhibitorsCholinesterase InhibitorsCrown EthersHumansMolecular StructureMonophenol MonooxygenaseProton Magnetic Resonance SpectroscopyStructure-Activity RelationshipSulfonamidesAcetylcholinesteraseAntioxidantsButyrylcholinesterasecalix(4)arene crown-4 etherCalixarenesCarbonic Anhydrase InhibitorsCholinesterase InhibitorsCrown EthersMonophenol MonooxygenaseSulfonamidesantioxidantCalix[4]azacrowncarbonic anhydraseenzyme inhibition

Identifiers

PMID32401067
PMCPMC7269057
OpenAlexW3024850461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.